ImmuSmol Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Employees
  • 10

Employees
  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $382K

  • Investors
  • 3

ImmuSmol General Information

Description

Developer of small molecule antibodies intended to block the mechanisms used by tumors to escape the surveillance of the immune system. The company's antibodies are used in the research, diagnostic and therapeutic applications, helping healthcare professionals in the visualization, quantification, and modulation of monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Diagnostic Equipment
Primary Office
  • 229 Cours De L Argonne
  • 33000 Bordeaux
  • France
+33 05 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuSmol Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 01-Apr-2018 $382K 00000 Completed Generating Revenue
2. Early Stage VC 23-Sep-2014 00000 00000 Completed Generating Revenue
1. Accelerator/Incubator 29-Jul-2014 $203K $203K Completed Generating Revenue
To view ImmuSmol’s complete valuation and funding history, request access »

ImmuSmol Patents

ImmuSmol Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201511291-D0 Agent which increases and/or mimics kynurenine and optional combination thereof with an immunotherapeutic Inactive 26-Jun-2015
AU-2015293833-A2 Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway Inactive 24-Jul-2014 000000000000
AU-2015293833-A1 Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway Inactive 24-Jul-2014 000000000000
EP-3172568-A1 Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway Inactive 24-Jul-2014 000000000000
GB-201413162-D0 Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway Inactive 24-Jul-2014 G01N33/57484
To view ImmuSmol’s complete patent history, request access »

ImmuSmol Executive Team (2)

Name Title Board Seat Contact Info
Alban Bessede Ph.D Founder & Chief Executive Officer
Loic Cerf Chief Operating Officer
To view ImmuSmol’s complete executive team members history, request access »

ImmuSmol Board Members (1)

Name Representing Role Since
Vincent Picq ImmuSmol Board Member 000 0000
To view ImmuSmol’s complete board members history, request access »

ImmuSmol Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmuSmol Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Eurostars Government Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Incubateur Régional d'Aquitaine Accelerator/Incubator Minority 000 0000 000000 0
To view ImmuSmol’s complete investors history, request access »